A randomized, double-blind, placebo-controlled, phase 2b Study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation

• Main Authors: Vincent J.-L., Ramesh M.K., Ernest D., Larosa S.P., Pachl J., Aikawa N., Hoste E., Levy H., Hirman J., Levi M., Daga M., Kutsogiannis D.J., Crowther M., Bernard G.R., Devriendt J., Puigserver J.V., Blanzaco D.U., Esmon C.T., Parrillo J.E., Guzzi L., Henderson S.J., Pothirat C., Mehta P., Fareed J., Talwar D., Tsuruta K., Gorelick K.J., Osawa Y., Kaul I.
• Format: Article
• Language: English
• Published: 2014
• Online Access: http://www.scopus.com/inward/record.url?eid=2-s2.0-84883615933&partnerID=40&md5=9793d68014c665f2d76264da148359b3; http://cmuir.cmu.ac.th/handle/6653943832/4137
• Institution: Chiang Mai University

Objectives:: To determine the safety and efficacy of recombinant thrombomodulin (ART-123) in patients with suspected sepsis-associated disseminated intravascular coagulation. design:: Phase 2b, international, multicenter, double-blind, randomized, placebo-controlled, parallel group, screening trial....